Notably, the utilization of anti-angiogenic therapies and local radiotherapy has shown promising results in extending overall survival (OS) in these patients.[80] Additionally, targeting aurora kinases (AURKA) inhibitors has shown potential in suppressing the growth of Rb1-negative SCLC cells, making it an attractive therapeutic approach for transformed SCLC patients. The gene discussed is AURKA; the disease is small cell lung carcinoma.